Background
Aim of the present study is to describe characteristics of COVID-19-related deaths and to compare the clinical phenotype and course of COVID-19-related deaths occurring in adults (<65 years) and older adults (≥65 years).
Method
Medical charts of 3,032 patients dying with COVID-19 in Italy (368 aged < 65 years and 2,664 aged ≥65 years) were revised to extract information on demographics, preexisting comorbidities, and in-hospital complications leading to death.
Results
Older adults (≥65 years) presented with a higher number of comorbidities compared to those aged <65 years (3.3 ± 1.9 vs 2.5 ± 1.8, p < .001). Prevalence of ischemic heart disease, atrial fibrillation, heart failure, stroke, hypertension, dementia, COPD, and chronic renal failure was higher in older patients (≥65 years), while obesity, chronic liver disease, and HIV infection were more common in younger adults (<65 years); 10.9% of younger patients (<65 years) had no comorbidities, compared to 3.2% of older patients (≥65 years). The younger adults had a higher rate of non-respiratory complications than older patients, including acute renal failure (30.0% vs 20.6%), acute cardiac injury (13.5% vs 10.3%), and superinfections (30.9% vs 9.8%).
Conclusions
Individuals dying with COVID-19 present with high levels of comorbidities, irrespective of age group, but a small proportion of deaths occur in healthy adults with no preexisting conditions. Non-respiratory complications are common, suggesting that the treatment of respiratory conditions needs to be combined with strategies to prevent and mitigate the effects of non-respiratory complications.
No differences were found between genders in terms of virological and immunological outcomes during long-term HAART. Nevertheless, a lower risk of clinical progression was reported among female patients with intermediate baseline viral load than in males.
We found little evidence of sex differences during antiretroviral treatment. Nevertheless, most of these studies were underpowered to detect sex differences and had limited follow-up at 6 or 12 months. Design of new gender-sensitive clinical trials with both prolonged follow-up and sample size representative of the current HIV prevalence among women are strongly needed to detect the likely sex differences of antiretroviral agents during HIV infection.
Background:Evidence on the efficacy of palliative care in persons with severe multiple
sclerosis (MS) is scarce.Objective:To assess the efficacy of a home-based palliative approach (HPA) for adults
with severe MS and their carers.Methods:Adults with severe MS-carer dyads were assigned (2:1 ratio) to either HPA or
usual care (UC). At each center, a multi-professional team delivered the
6-month intervention. A blind examiner assessed dyads at baseline, 3 months,
and 6 months. Primary outcome measures were Palliative care Outcome
Scale-Symptoms-MS (POS-S-MS) and Schedule for the Evaluation of Individual
Quality of Life-Direct Weighting (SEIQoL-DW, not assessed in severely
cognitively compromised patients).Results:Of 78 dyads randomized, 76 (50 HPA, 26 UC) were analyzed. Symptom burden
(POS-S-MS) significantly reduced in HPA group compared to UC
(p = 0.047). Effect size was 0.20 at 3 months and 0.32
at 6 months, and statistical significance was borderline in per-protocol
analysis (p = 0.062). Changes in SEIQoL-DW index did not
differ in the two groups, as changes in secondary patient and carer
outcomes.Conclusion:HPA slightly reduced symptoms burden. We found no evidence of HPA efficacy on
patient quality of life and on secondary outcomes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.